Patents Examined by Cecilia M. Jaisle
  • Patent number: 8623866
    Abstract: The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, R1, R2, R3, R4, R5 and R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: January 7, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Alexander Flohr, Katrin Groebke Zbinden, Felix Gruber, Matthias Koerner, Bernd Kuhn, Jens-Uwe Peters, Rosa Maria Rodriguez-Sarmiento
  • Patent number: 8623870
    Abstract: Compounds of the formula (I), in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: January 7, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Patent number: 8614223
    Abstract: The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: December 24, 2013
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: John H. van Duzer, Ralph Mazitschek, Yanbing Ding, Nan Yu, Yun Cao, Yong Liu
  • Patent number: 8609662
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acetylcholine receptors (NACHR) ligands.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 17, 2013
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Mathias Frederiksen, Konstanze Hurth, Bernard Lucien Roy
  • Patent number: 8604036
    Abstract: Compounds of the formula (I), in which R1, R2, R3, W and D have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: December 10, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • Patent number: 8598176
    Abstract: A pyridazine compound of the formula: has an excellent plant disease controlling effect.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: December 3, 2013
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Akio Manabe
  • Patent number: 8598345
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: December 3, 2013
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Charles David Weaver, Alice L. Rodriguez, Andrew S. Felts, Carrie K. Jones, Brittney S. Bates
  • Patent number: 8586588
    Abstract: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 19, 2013
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Thomas R. Bailey, Nadine C. Becknell, Sankar Chatterjee, Derek Dunn, Greg A. Hostetler, Robert L. Hudkins, Kurt A. Josef, Lars J. S. Knutsen, Ming Tao, Allison L. Zulli
  • Patent number: 8580781
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R4? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: November 12, 2013
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
  • Patent number: 8580791
    Abstract: Novel acid addition salts of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole of following formula are disclosed, particularly a crystalline form of a bis-dihydrogenphosphate salt: Such compounds have particular advantages with regard to treatment of picornaviruses. Related pharmaceutical compositions and methods of treating a picornavirus infection are also disclosed.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: November 12, 2013
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Jane Ryan, Margaret Anne Butt
  • Patent number: 8575167
    Abstract: The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R1, R2, R3, R4, R11, R12, R13 and R14 are each independently a hydrogen atom or a substituent, or R1 and R11 in combination, R2 and R12 in combination, R3 and R13 in combination, or R4 and R14 in combination optionally form an oxo group, or R2 and R4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: November 5, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiko Taniguchi, Kenichi Miyata, Osamu Kubo
  • Patent number: 8569488
    Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 29, 2013
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development
    Inventors: Eric D. Dowdy, Kenneth M. Kent, Norma J. Tom, Vahid Zia
  • Patent number: 8569487
    Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: October 29, 2013
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development
    Inventors: Steven S. Bondy, Terrence C. Dahl, David A. Oare, Reza Oliyai, Winston C. Tse, Vahid Zia
  • Patent number: 8563558
    Abstract: The present disclosure provides pyridine urea compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4, R5, V and W are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: October 22, 2013
    Assignee: Confluence Life Sciences, Inc.
    Inventors: Shaun R. Selness, Joseph B. Monahan, John F. Schindler, Balekudru Devadas, Susan L. Hockerman
  • Patent number: 8552182
    Abstract: A method for producing a 3-(substituted oxy)-4-pyridazinol compound represented by the following general formula (I): comprising reacting a compound represented by the following general formula (III): with a compound represented by the following general formula (IV): MO—R2??(IV). The compound represented by the general formula (I) can be reacted with a compound represented by the following general formula (VI): to provide a compound of general formula (V): Each of the groups in the formulas is defined. The compounds of general formulas (I) and (V) can be obtained in a high yield and with high selectivity at a low cost, and therefore various functional and active substances can be advantageously synthesized using the compounds as a medicine, an agricultural chemical, a functional material, or an intermediate thereof.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 8, 2013
    Assignee: Mitsui Chemicals Agro, Inc.
    Inventors: Hideaki Ikishima, Nobuhiro Kondo, Takeshi Takada, Yoshihisa Tsukamoto, Hidetake Yoshitomi, Haruko Mita
  • Patent number: 8546396
    Abstract: The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: October 1, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • Patent number: 8541414
    Abstract: A pyridazinone compound represented by the formula (I) has excellent effect on weed control and is useful as an active ingredient of herbicides.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: September 24, 2013
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Toshiyuki Kiji, Takafumi Fusaka
  • Patent number: 8536168
    Abstract: The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: September 17, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Feng He, Rishi Kumar Jain, Rajesh Karki, Joseph Kelleher, III, John Lei, Luis Llamas, Michael A. Mcewan, Karen Miller-Moslin, Lawrence Bias Perez, Stefan Peukert, Naeem Yusuff
  • Patent number: 8507490
    Abstract: The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C—R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or trifluoromethyl; R4 is pyrrolidinyl, morpholinyl or pyridyl, amino or dimethylamino; R5 is trifluoromethyl or methylsulfonyl; R6 is hydrogen or methyl; and R7, R8, R9, R10 and R11 are independently hydrogen fluoro, cyano, chloro, methyl, trifluoromethyl, trifluoromethoxy or methylsulfonyl, provided that at least two of R7, R8, R9, R10 and R11 are hydrogen useful in the treatment of cancer.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: August 13, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Jeffrey Daniel Cohen, Philip Arthur Hipskind, Karen Lynn Lobb, Daniel Jon Sall, Michelle Lee Thompson, Takako Wilson (nee Takakuwa)
  • Patent number: 8507491
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan